# Can FOXO4-DRI influence pulmonary hypertension and senescent cell dynamics?

Canonical source: https://retacompare.com/research/can-foxo4-dri-influence-pulmonary-hypertension-and-senescent-cell-dynamics

Peptide Longevity Q&A · 2023-02-21


    Research indicates that FOXO4-DRI, a cell-permeable peptide, may be involved in eliminating senescent cells, which could affect pulmonary hypertension development and progression. In preclinical models, FOXO4-DRI treatment showed changes in pulmonary endothelial cells and hemodynamics related to senescence.

 What the research shows

The study investigated the role of senescent cells (SCs) in pulmonary arterial hypertension (PAH) using human patient samples and murine models. Key markers of senescence and DNA damage, such as p16, p21, and γ-H2AX, were measured in both contexts. The researchers employed various methods to clear SCs, including the FOXO4-DRI peptide, senolytic drugs like ABT263, and a suicide gene construct in specific mouse models. The research monitored the impact of SC clearance on pulmonary hypertension in mice under different conditions, including normoxia, chronic hypoxia, and exposure to Sugen, as well as in rats treated with monocrotaline.

 Why it matters for longevity

The findings suggest that targeting senescent cells with FOXO4-DRI could have implications for managing pulmonary hypertension, a condition that can severely impact healthspan and quality of life. As senescence is linked to aging and various chronic diseases, understanding how FOXO4-DRI influences SC dynamics may provide insights into potential therapeutic strategies for age-related vascular conditions. By potentially improving pulmonary vascular health, FOXO4-DRI may contribute to extending healthspan, particularly in older populations.

 Key findings at a glance

FOXO4-DRI is a cell-permeable peptide used to eliminate senescent cells in research models.

Increased levels of senescence markers were observed in patients with pulmonary arterial hypertension.

SC clearance using FOXO4-DRI affected pulmonary endothelial cells and hemodynamics.

The study found that eliminating senescent cells might worsen pulmonary hemodynamics in certain contexts.

FOXO4-DRI was part of a broader investigation into the effects of senolytic treatments on pulmonary hypertension.

 How FOXO4-DRI works (background)

FOXO4-DRI functions by interfering with the p53 signaling pathway, which is critical in regulating cell senescence and apoptosis. By disrupting this pathway, FOXO4-DRI promotes the clearance of senescent cells, which are often characterized by a pro-inflammatory secretory phenotype. In the context of pulmonary hypertension, the accumulation of senescent cells can lead to vascular remodeling and impaired endothelial function. Therefore, the application of FOXO4-DRI may help mitigate these effects by reducing the burden of senescent cells in pulmonary tissues.

 Safety, caveats, and what we don't yet know

While the study provides valuable insights into the role of FOXO4-DRI in clearing senescent cells, it is important to note that this research is primarily preclinical. The long-term effects and safety of FOXO4-DRI in humans have not yet been established. Furthermore, the implications of senescent cell clearance on overall health and various age-related conditions remain to be fully understood. Future studies are needed to explore the potential benefits and risks of FOXO4-DRI in diverse populations and clinical settings.

 Bottom line

FOXO4-DRI may influence pulmonary hypertension by targeting senescent cells, with implications for healthspan and vascular health. However, further research is necessary to clarify its effects and safety in human populations.

 Related questions

 How does FOXO4-DRI affect aging-related diseases?

Research indicates that FOXO4-DRI may play a role in reducing the burden of senescent cells, potentially impacting various aging-related diseases by improving tissue function and reducing inflammation.

 What are the potential benefits of senolytics like FOXO4-DRI?

Senolytics, including FOXO4-DRI, are being studied for their ability to clear senescent cells, which could improve tissue health and function, thereby potentially extending healthspan and mitigating age-related conditions.

 Is FOXO4-DRI safe for long-term use?

Current research on FOXO4-DRI is limited to preclinical studies, and its long-term safety and efficacy in humans have not yet been established, necessitating further investigation before clinical application.

 Source: PubMed · Circulation · published 2023-02-21.

## Sources

- PubMed · Circulation: https://pubmed.ncbi.nlm.nih.gov/36515093/